105 related articles for article (PubMed ID: 31531954)
1. Development of a ZHER3-Affibody-Targeted Nano-Vector for Gene Delivery to HER3-Overexpressed Breast Cancer Cells.
Nazari M; Zamani Koukhaloo S; Mousavi S; Minai-Tehrani A; Emamzadeh R; Cheraghi R
Macromol Biosci; 2019 Nov; 19(11):e1900159. PubMed ID: 31531954
[TBL] [Abstract][Full Text] [Related]
2. Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer.
Nazari M; Minai-Tehrani A; Mousavi S; Zamani Koukhaloo S; Emamzadeh R
Int J Biol Macromol; 2021 Oct; 189():948-955. PubMed ID: 34455002
[TBL] [Abstract][Full Text] [Related]
3. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
[No Abstract] [Full Text] [Related]
4. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
5. Development of a Targeted anti-HER2 scFv Chimeric Peptide for Gene Delivery into HER2-Positive Breast Cancer Cells.
Cheraghi R; Nazari M; Alipour M; Majidi A; Hosseinkhani S
Int J Pharm; 2016 Dec; 515(1-2):632-643. PubMed ID: 27825868
[TBL] [Abstract][Full Text] [Related]
6. Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors.
Liu H; Jia D; Yuan F; Wang F; Wei D; Tang X; Tian B; Zheng S; Sun R; Shi J; Fan Q
Int J Pharm; 2022 Apr; 617():121609. PubMed ID: 35217073
[TBL] [Abstract][Full Text] [Related]
7. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
8. Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.
Da Pieve C; Allott L; Martins CD; Vardon A; Ciobota DM; Kramer-Marek G; Smith G
Bioconjug Chem; 2016 Aug; 27(8):1839-49. PubMed ID: 27357023
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
11. Cellular effects of HER3-specific affibody molecules.
Göstring L; Malm M; Höidén-Guthenberg I; Frejd FY; Ståhl S; Löfblom J; Gedda L
PLoS One; 2012; 7(6):e40023. PubMed ID: 22768204
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery.
Soltani F; Sankian M; Hatefi A; Ramezani M
Int J Pharm; 2013 Jan; 441(1-2):307-15. PubMed ID: 23200954
[TBL] [Abstract][Full Text] [Related]
14. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
15. A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity.
Nazari M; Emamzadeh R; Jahanpanah M; Yazdani E; Radmanesh R
Int J Biol Macromol; 2022 Oct; 219():1122-1134. PubMed ID: 36041577
[TBL] [Abstract][Full Text] [Related]
16. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
17. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
[TBL] [Abstract][Full Text] [Related]
19. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
20. Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR.
Nguyen LT; Yang XZ; Du X; Wang JW; Zhang R; Zhao J; Wang FJ; Dong Y; Li PF
Amino Acids; 2015 May; 47(5):997-1006. PubMed ID: 25655386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]